Financing channel feed

Quest for safe mus­carinic re­cep­tor ag­o­nists to tack­le dis­as­ter prone CNS field steers Karuna to $75M IPO

6 years ago

Luck and uni­corns? Who needs that? San­té Ven­tures’ new $250M fund is look­ing for biotech up­starts

6 years ago

Part­nered with Genen­tech and Mi­crosoft, this biotech be­lieves it can lever­age its knowl­edge of the im­mune sys­tem in­to a $230M-plus IPO

6 years ago

Se­quoia helps fu­el Whole Bio­me's planned launch for 'med­ical pro­bi­otic­s' in $35M Se­ries B

6 years ago

Third Rock un­veils liq­uid biop­sy biotech, lead­ing $110M bet it can Thrive in ear­ly can­cer de­tec­tion

6 years ago

Ready to har­vest its PD-L1, Al­pham­ab re­loads with $60M to nur­ture the bis­pe­cif­ic patch

6 years ago
China

IPO boom: An­ti­body ex­perts at Gen­mab out­line glob­al am­bi­tion in pitch for $500M

6 years ago

5 cash-hun­gry biotechs crowd in­to Nas­daq in search of a $600M-plus wind­fall

6 years ago

Ideaya wraps $50M IPO to fu­el clin­i­cal dri­ve on syn­thet­ic lethal­i­ty

6 years ago

Ed Kaye is tak­ing his fledg­ling biotech to Wall Street, look­ing for a new in­jec­tion of cash

6 years ago
Startups

Tread­ing on Nas­daq turf, NYSE cuts list­ing fees to woo biotech

6 years ago
R&D

Bi­cy­cle rais­es $61M in down­sized IPO, join­ing fel­low biotechs on Nas­daq who have hauled in $1.6B col­lec­tive­ly

6 years ago

Ex-FDA com­mish Scott Got­tlieb makes a quick jump back on­to the mon­ey side of biotech

6 years ago
People

Ad­di­tion­al back­ing arms Schrödinger with $110M in first ven­ture round — shin­ing a spot­light on its own pipeline

6 years ago

As UK biotech gains steam, Syn­cona launch­es new Treg play­er while Cam­bridge spin­out ex­pands Se­ries A

6 years ago
Startups

All in on nov­el tar­get GSK-3β, Ac­tu­ate Ther­a­peu­tics rais­es $21M+ to bankroll am­bi­tious PhI/II

6 years ago

Mi­cro­bio­me up­start Vedan­ta gets an ex­tra $18.5M in the bank, wrap­ping up $45.5 Se­ries C round

6 years ago

They got bounced out of Alex­ion. Now David Hal­lal and Vikas Sin­ha are back with $150M and a fo­cus on cell and gene ther­a­pies

6 years ago
Startups

Philo­gen who? A low pro­file but phar­ma-con­nect­ed Ital­ian-Swiss hy­brid steps out with $68M for a fi­nal push over the PhI­II fin­ish line

6 years ago
R&D

Four biotechs haul in $303M+ from a fresh burst of IPOs

7 years ago

Bel­gium's liv­er-fo­cused stem cell ther­a­py de­vel­op­er Promethera rais­es $44M+ in lat­est round

7 years ago

Weeks af­ter a Pfiz­er/Mer­ck KGaA break­down, Clo­vis gam­bles on a $175M loan to fin­ish a glob­al PhI­II PARP/PD-1 com­bo study

7 years ago
R&D

Co­di­ak Bio­sciences out­lines a new fo­cus for its ex­o­some plat­form in $86M IPO fil­ing

7 years ago

Vow­ing to spark a rev­o­lu­tion in small mol­e­cule R&D, Vi­vid­ion equips it­self with an ex­tra $82M for the fi­nal stretch to the clin­ic

7 years ago
Startups
First page Previous page 111112113114115116117 Next page Last page
A service from the Financial Times